4//SEC Filing
TIMBIE THOMAS E 4
Accession 0001209191-22-044621
CIK 0001630627other
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 6:01 PM ET
Size
11.6 KB
Accession
0001209191-22-044621
Insider Transaction Report
Form 4
TIMBIE THOMAS E
Director
Transactions
- Sale
Common Stock
2022-08-03$18.85/sh−96,879$1,825,869→ 1,552,190 total(indirect: By Trust) - Sale
Common Stock
2022-08-04$18.56/sh−48,217$894,724→ 1,503,973 total(indirect: By Trust) - Sale
Common Stock
2022-08-05$19.04/sh−4,904$93,373→ 1,499,069 total(indirect: By Trust)
Holdings
- 2,295
Common Stock
- 385,000(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.50 to $19.17 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.50 to $19.03 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.91 to $19.34 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on May 17, 2023 subject to Reporting Person's providing continued service to Issuer through the vesting date.
Documents
Issuer
TREACE MEDICAL CONCEPTS, INC.
CIK 0001630627
Entity typeother
Related Parties
1- filerCIK 0001188309
Filing Metadata
- Form type
- 4
- Filed
- Aug 4, 8:00 PM ET
- Accepted
- Aug 5, 6:01 PM ET
- Size
- 11.6 KB